SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PRECLINICAL AND CLINICAL DATA ON ROVADICITINIB PRESENTED AT EHA 2025

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Group presented orally the results of preclinical and a Phase Ib clinical study of rovadicitinib for the treatment of acute graft-versus-host disease (aGVHD) at the 2025 European Hematology Association (EHA) Congress: the overall response rate (ORR) at 28 days was 84.6%, with a median response time of 4 days and a 12-month overall survival rate of 92.3%.

aGVHD is one of the major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and can be life-threatening. Glucocorticoids are currently the standard first-line treatment for aGVHD. However, more than half of patients either do not respond to glucocorticoids, or experience disease progression after an initial response, which results in extremely high mortality rates. As an oral, selective JAK1/2 and ROCK1/2 inhibitor, rovadicitinib targets multiple pathways involved in aGVHD, offering a promising alternative treatment option for patients with steroid-refractory (SR) aGVHD.

Results[1]:

1. Immunomodulatory mechanism of rovadicitinib

Regulation of T cell subsets: It reduced the infiltration of pro-inflammatory Th1 and Tc1 cells in the small intestine of aGVHD mouse models while increasing the number of anti-inflammatory Treg cells, thereby improving the intestinal immune microenvironment.

Inhibition of dendritic cell (DC) function: It downregulated the secretion of co-stimulatory molecules (CD80, CD86, CD40), chemokines (Cxcl9, Cxcl10), and IL-12, thereby weakening DC-mediated T cell activation and differentiation.

Blocking the positive inflammatory feedback loop: Its dual inhibitory effect on T cells and DCs disrupted the positive feedback loop of pro-inflammatory cytokines, ultimately alleviating the pathological progression of aGVHD.

2. Clinical advantages of rovadicitinib

Rapid onset of action and sustained response: Clinical data showed an ORR of 84.6% and an intestinal response rate of 80% at 28 days, a median overall response time of only 4 days, and a 12-month survival rate as high as 92.3%.

Steroid tapering: Within 56 days, 38.5% of patients completely discontinued steroid use, which significantly reduced the side effects of long-term immunosuppression.

Rovadicitinib is the world's first dual JAK/ROCK pathway inhibitor. The results mark another of our breakthroughs in the treatment of graft-versus-host disease (GVHD). In addition, a Phase III clinical trial of rovadicitinib for the treatment of chronic graft-versus-host disease (cGVHD) has been initiated, with patient enrollment currently underway. The Group will continue to focus on the field of GVHD, with a view to providing patients with better treatment options.

Source:

[1] Zhuoyue Shi, Hengwei Wu, Jimin Shi, et al. JAK/ROCK Inhibition with Rovadicitinib suppresses murine and human Acute Graft-Versus-Host Disease: the results of preclinical and a phase 1b study. EHA 2025.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 18 June 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.